Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Vet Parasitol ; 328: 110179, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38579607

RESUMO

In this study the efficacy of an intramuscular formulation of toltrazuril combined with gleptoferron for the control of porcine cystoisosporosis caused by Cystoisospora suis was investigated. The study was carried out on three Belgian farms with a confirmed history of C. suis infections. As none of the farms implemented a standardized toltrazuril treatment regimen for their piglets, the presence of resistant C. suis strains seems improbable. In total 90 litters, representing 1249 piglets, were included in the study and randomly allocated to either the treatment or control group. Piglets in the treatment group received a single intramuscular injection, containing 45 mg toltrazuril and 200 mg gleptoferron, between 1 and 3 days of age. Piglets in the control group received a single injection with only 200 mg gleptoferron. The effect of treatment on oocyst excretion, expressed in oocysts per gram of feces (OPG), average daily weight gain (ADG) and mortality was determined both pre- and post-weaning. A significant decrease in OPG as well as a decrease in the number of litters (pre-weaning) and pens (post-weaning) that tested positive for cystoisosporosis, was observed in the treated animals compared to the controls. Furthermore, treatment resulted in an increased ADG during the period from day 1 to day 21 (p-value: 0.03881). There was no significant difference in mortality observed between the treatment group to the control group (p-value: 0.2167). To our knowledge, this is the first report on the effect of toltrazuril on oocyst excretion after weaning. This finding highlights the potential long-term benefits of the treatment beyond the initial administration.


Assuntos
Coccidiose , Coccidiostáticos , Oocistos , Doenças dos Suínos , Triazinas , Desmame , Animais , Triazinas/administração & dosagem , Triazinas/farmacologia , Suínos , Doenças dos Suínos/tratamento farmacológico , Doenças dos Suínos/parasitologia , Coccidiose/tratamento farmacológico , Coccidiose/veterinária , Coccidiose/parasitologia , Oocistos/efeitos dos fármacos , Coccidiostáticos/administração & dosagem , Coccidiostáticos/farmacologia , Coccidiostáticos/uso terapêutico , Sarcocystidae/efeitos dos fármacos , Animais Recém-Nascidos , Fezes/parasitologia , Injeções Intramusculares/veterinária , Aumento de Peso/efeitos dos fármacos
2.
Sci Rep ; 13(1): 20488, 2023 11 22.
Artigo em Inglês | MEDLINE | ID: mdl-37993516

RESUMO

The development of effective recombinant vaccines against parasitic nematodes has been challenging and so far mostly unsuccessful. This has also been the case for Ostertagia ostertagi, an economically important abomasal nematode in cattle, applying recombinant versions of the protective native activation-associated secreted proteins (ASP). To gain insight in key elements required to trigger a protective immune response, the protein structure and N-glycosylation of the native ASP and a non-protective Pichia pastoris recombinant ASP were compared. Both antigens had a highly comparable protein structure, but different N-glycan composition. After mimicking the native ASP N-glycosylation via the expression in Nicotiana benthamiana plants, immunisation of calves with these plant-produced recombinants resulted in a significant reduction of 39% in parasite egg output, comparable to the protective efficacy of the native antigen. This study provides a valuable workflow for the development of recombinant vaccines against other parasitic nematodes.


Assuntos
Doenças dos Bovinos , Ostertagíase , Bovinos , Animais , Ostertagia/genética , Ostertagíase/prevenção & controle , Ostertagíase/veterinária , Vacinação/veterinária , Vacinas Sintéticas/genética , Proteínas Recombinantes/genética , Contagem de Ovos de Parasitas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA